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Abstract
Background: Procalcitonin (PCT) is a well-known marker for 
bacterial infection; however, the clinical significance of PCT 
in the long-term prognosis after colorectal cancer (CRC) sur-
gery remains unclear. Methods: This is a retrospective review 
of 277 patients that underwent CRC surgery to investigate 
the relationship between preoperative PCT, clinicopatho-
logical condition, cancer-specific overall survival (OS), and 
relapse-free survival (RFS). Results: Median follow-up inter-
val was 5.0 years in all patients. Thirty-six patients developed 
recurrence, and 46 patients died due to recurrences or me-
tastases of CRC. Preoperative PCT levels were highest in 
Stage IV patients. The cancer-specific OS in patients with 
Stage IV/PCT ≤0.05 ng/mL was significantly higher than 
those with Stage IV/PCT >0.05 ng/mL (3 years survival; 42.3 
vs. 14.3%, p = 0.0413). On multivariate analysis, gender, TNM 
classification, and PCT were identified as significant risk fac-
tors for cancer-specific OS in patients with Stage I–III CRC. 
The cancer-specific OS rate of these patients with PCT ≥0.08 
ng/mL, compared with PCT <0.08 ng/mL, was significantly 
decreased (5 years survival; 59.1 vs. 92.7%, p < 0.0001). TNM 
classification was finally identified as an independent risk 
factor for cancer-specific RFS in these patients by multivari-
ate analysis. Conclusion: High preoperative PCT values in 
CRC patients appeared to be associated with poor OS but 
not RFS following surgical treatments.
© 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Colorectal cancer (CRC) is the third most common 
cancer worldwide. Despite the development of new che-
motherapy regimens and the progress of laparoscopic 
surgical techniques, the overall survival (OS) is still poor 
in most patients with advanced CRC [1]. Digestive can-
cer, especially CRC, is known to induce local inflamma-
tion according to cancer progression. Local inflammation 
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in the tumor microenvironment augments angiogenesis, 
leukocyte accumulation, and fibrosis, which accelerates 
cancer progression [2]. In this concept, several systemic 
inflammation-related markers were demonstrated to 
predict cancer-specific prognosis, such as the C-reactive 
protein (CRP), the Glasgow Prognostic Score (GPS) [3], 
the neutrophil-to-lymphocyte ratio [4], and the prognos-
tic nutritional index (PNI) [5]. A large population study 
from Proctor et al. [6] revealed that systemic inflamma-
tion-based scores, particularly, modified GPS (mGPS) 
and PNI, have a prognostic value in cancer, independent 
of tumor origin.
Procalcitonin (PCT) is a polypeptide consisting of 116 
amino acids and is the precursor of calcitonin. Assicot et 
al. [7] first described the role of PCT under inflammatory 
conditions, especially sepsis and bacterial infections. 
Since then, it has been reported to be a useful marker for 
diagnosis of bacterial infections, septic conditions, and 
the severity of sepsis [8, 9]. Recent studies have reported 
significant relationships between PCT and malignant tu-
mors. Cotoi et al. [10] demonstrated that PCT is indepen-
dently associated with the risk for cancer-specific mortal-
ity in apparently healthy men. Moreover, elevation of 
PCT is significantly associated with the incidence of co-
lon cancer [10]. Herein, we assess the clinical and prog-
nostic implication of preoperative PCT in CRC patients, 
comparing inflammation-based prognostic scores, such 
as mGPS and PNI.
Materials and Methods
Patients
We retrospectively reviewed clinical and laboratory data of 339 
consecutive CRC patients who underwent surgical treatment be-
tween October 2010 and December 2014 at Shiga University of 
Medical Science Hospital (Shiga, Japan). Laboratory analyses of 
serum PCT, CRP, albumin, carcinoembryonic antigen (CEA), and 
CA19-9 were routinely performed before surgery. Timing of blood 
sampling is basically in the day before surgery or before induction 
of anesthesia. PCT was measured by Elecsys® Brahms PCT and 
Cobas 8000® (Roche Diagnostics Corporation, Tokyo, Japan; 
range 0.05–100 ng/mL) [11]. The mGPS and PNI were evaluated 
as previously described [5, 6]. Disease stages of CRC were defined 
according to the TNM Classification of Malignant Tumors 7th edi-
tion published from the UICC. Postoperative infectious complica-
tions (POIs) were defined according to the Centers for Disease 
Control and Prevention surveillance definition [12]. POI such as 
deep surgical site infection (SSI) and superficial SSI that were con-
nected with the site of anastomotic leakage was counted as anasto-
motic leakage.
Statistical Analysis
Qualitative variables were indicated as numbers and compared 
with Fisher’s exact test or χ2 test. Plausibility of normal distribution 
for continuous variables was evaluated by the one-sample Shapiro-
Wilk test. Continuous variables with normal distribution are ex-
pressed as mean ± standard error and were compared using Stu-
dent t tests. Continuous variables without normal distribution are 
expressed as median and quartiles/90 percentile, which were eval-
uated with Wilcoxon signed-rank test. The best cutoff value for 
continuous variables to determine cancer-specific OS and relapse-
free survival (RFS) was calculated by receiver operating character-
Table 1. Clinical, pathological, and biochemical characteristics and PCT between cancer-specific non-survivors 
and survivors in all 277 patients with CRC
Non-survivors (n = 46) Survivors (n = 231) p value
Gender (male/female) 33/13 128/103 0.0490
Age, years old 67±1.7 68±0.7 0.0493
CEA, ng/mL 287±211 8.6±1.0 0.0032
CA19-9, U/mL 172±82 18.4±1.0 <0.0001
PNI 42.5±1.0 45.5±0.4 0.0049
Preoperative PCT, ng/mL 0 (0–0.0575) 0 (0–0) 0.0004
PCT at postoperative day 1, ng/mL 0.670 (0.235–2.6175) 0.215 (0.07–0.7675) 0.0003
mGPS (0/1/2) 30/5/11 208/9/14 0.0003
Site of tumor (right side/left side) 13/33 59/172 0.8568
Tumor diameter, mm 52.6±1.6 39.7±1.6 0.0007
Differentiation of cancer (well, mod/others) 43/3 218/13 0.8152
TNM classification (stage 0/I/II/III/IV) 0/1/5/15/25 12/85/63/64/7 <0.0001
Curative resection (CurA/B/C) 20/3/23 223/2/6 0.0894
POI (positive/negative) 28/18 198/33 0.0003
Data are expressed as mean±standard error or median (25–75 percentile). CRC, colorectal cancer; mGPS, 
modified Glasgow Prognostic Score; PNI, prognostic nutritional index; PCT, procalcitonin; POI, postoperative 
infectious complication.
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istic curve analysis. To examine the clinical significance of patho-
physiological parameters on cancer-specific OS and RFS, survival 
analysis was performed by the Kaplan-Meier method. Hazard ra-
tios with 95% confidence intervals were calculated with univariate 
and multivariate analysis using the Cox proportional hazard mod-
el to identify risk factors for cancer-specific OS and RFS. Statistical 
analysis was performed using JMP14 (SAS Institute Inc., Cary, NC, 
USA) and IBM SPSS ver. 25 (IBM Corp, Tokyo, Japan). A p value 
<0.05 was considered statistically significant.
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Fig. 1. The relation of PCT and cancer-prognosis in patients with Stage IV CRC. a Preoperative PCT levels di-
vided by CRC staging. *p < 0.05 versus Stage 0, I, and III. b Cancer-specific OS in Stage IV CRC patients divided 
by PCT level. 3 years survival rate, PCT ≤0.05 ng/mL; 42.3% versus PCT >0.05 ng/mL; 14.3%, log-rank test p = 







Of 339 consecutive CRC patients, 34 patients had no 
PCT measurement before surgery. One patient died with-
in 30 days after surgery. Six patients had infectious condi-
tions before surgery. Twenty-one patients were excluded 
because of neoadjuvant chemotherapy and/or irradia-
tion. Finally, 277 patients were analyzed in this study.
The median follow-up interval was 5.00 years in all pa-
tients (survivors: 5.05 years, cancer-specific death: 2.04 
years). Thirty-six patients developed recurrence and 46 pa-
tients died due to recurrences or metastases of CRC. The 
distributions of gender, age, CEA, CA19-9, PNI, preopera-
tive PCT, tumor diameter, TNM classification, curative re-
section, mGPS, and POI were significantly associated with 
cancer-specific patients’ mortality (Table 1). Fifty-one POIs 
in 48 patients took place: 19 superficial SSI, 11 anastomotic 
Table 2. The relationship between clinical, pathologic, and biochemical characteristics and cancer-specific OS in 
232 patients with stage I, II, and III CRC: univariate and multivariate analysis
Univariate 
analysis HR (95% CI)
p value Multivariate 
analysis HR (95% CI)
p value
Gender
Female n = 132 1 0.0393 1 0.0311
Male n = 100 3.166 (1.058–9.471) 3.360 (1.117–10.11)
Age
<70 n = 116 1 0.2676
≥70 n = 116 1.659 (0.678–4.059)
Site of tumor
Left side n = 175 1 0.3750
Right side n = 57 0.574 (0.168–1.957)
Differentiation
Well, mod n = 216 1 0.0551
Others n = 16 3.330 (0.974–11.38)
Tumor diameter
<38 mm n = 126 1 0.0646
≥38 mm n = 106 2.379 (0.949–5.964)
TNM classification
Stage I, II n = 154 1 0.0006 1 0.0039
Stage III n = 78 5.908 (2.147–16.25) 4.764 (1.652–13.73)
Preoperative PCT
<0.08 ng/mL n = 217 1 0.0070 1 0.0448
≥0.08 ng/mL n = 15 4.542 (1.512–13.64) 3.851 (1.176–12.62)
CEA
<7.0 ng/mL n = 169 1 0.0025 1 0.0843
≥7.0 ng/mL n = 63 3.907 (1.617–9.440) 2.296 (0.894–5.897)
CA19-9
<24 U/mL n = 178 1 0.0138 1 0.3294
≥24 U/mL n = 54 3.025 (1.253–7.301) 1.601 (0.622–4.124)
mGPS
0, 1 n = 216 1 0.5001
2 n = 16 1.653 (0.383–7.128)
PNI
≥45 n = 102 1 0.8522
<45 n = 130 1.087 (0.450–2.624)
POI
Negative n = 195 1 0.0644
Positive n = 37 2.456 (0.947–6.418)
OS, overall survival; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; mGPS, modified 
Glasgow Prognostic Score; PNI, prognostic nutritional index; PCT, procalcitonin; POI, postoperative infectious 
complication.
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leakages, 5 enteritis, 5 catheter-related blood stream infec-
tions, 3 intra-abdominal abscesses, 3 deep SSI, 2 pneumo-
nias, 2 small intestinal perforations, and 1 urinary-tract in-
fection. We observed overlapped POI in 3 patients. The 
PCT levels at POD1 in patients with POI (0.54 [0.17–2.41] 
ng/mL) was significantly higher than those in patients with-
out POI (0.22 [0.07–0.89] ng/mL). Preoperative PCT levels 
according to tumor staging and cancer-related prognosis in 
patients with Stage 0 and IV CRC.
Preoperative PCT levels in Stage IV patients were sig-
nificantly elevated compared to those in Stage 0, I, and III 
patients (Fig. 1a). Cancer-specific OS rate in Stage IV pa-
tients with preoperative PCT ≤0.05 ng/mL was signifi-
cantly higher than those with preoperative PCT >0.05 ng/
mL group (Fig. 1b). On the other hand, preoperative PCT 
were under detectable levels in Stage 0 patients. There was 
no recurrence and mortality in these patients during 
5-year follow-up period.
Table 3. The relationship between clinical, pathologic, and biochemical characteristics and cancer-specific RFS 
in 232 patients with stage I, II, and III CRC: univariate and multivariate analysis
Univariate analysis 
HR (95% CI)




Female n = 132 1 0.1365
Male n = 100 1.720 (0.842–3.511)
Age
<70 n = 116 1 0.7015
≥70 n = 116 1.138 (0.587–2.209)
Site of tumor
Left side n = 175 1 0.3440
Right side n = 57 0.654 (0.271–1.576)
Differentiation
Well, mod n = 216 1 0.1292
Others n = 16 2.241 (0.790–6.356)
Tumor diameter
<38 mm n = 126 1 0.0093 1 0.0997
≥38 mm n = 106 2.526 (1.256–5.078) 1.834 (0.897–3.989)
TNM classification
Stage I, II n = 154 1 <0.0001 1 0.0005
Stage III n = 78 4.174 (2.076–8.391) 3.543 (1.743–7.203)
PCT
<0.08 ng/mL n = 217 1 0.1567
≥0.08 ng/mL n = 15 2.123 (0.749–6.018)
CEA
<7.0 ng/mL n = 169 1 0.0422 1 0.3719
≥7.0 ng/mL n = 63 2.017 (1.025–3.971) 1.377 (0.6824–2.778)
CA19-9
<24 U/mL n = 178 1 0.0551
≥24 U/mL n = 54 1.980 (0.985–3.980)
mGPS
0, 1 n = 216 1 0.2183
2 n = 16 1.924 (0.679–5.451)
PNI
≥45 n = 102 1 0.7946
<45 n = 130 1.092 (0.5617–2.124)
POI
Negative n = 195 1 0.0211 1 0.0940
Positive n = 37 2.371 (1.138–4.949) 1.892 (0.890–3.989)
RFS, relapse-free survival; CRC, colorectal cancer; HR, hazard ratio; CI, confidence interval; mGPS, modified 






Preoperative PCT and Cancer-Related Prognosis in 
232 Stage I–III Patients
We, therefore, analyzed the risk factors of cancer-spe-
cific OS in 232 Stage I–III patients. Gender, TNM classi-
fication, preoperative PCT, CEA, and CA19-9 were iden-
tified as significant risk factors for cancer-specific OS in 
these patients by univariate analysis. In the multivariate 
analysis, gender, TNM classification, and PCT were inde-
pendently associated with cancer-specific OS in these pa-
tients (Table 2). The cancer-specific OS rate in these pa-
tients with PCT ≥0.08 ng/mL was significantly decreased 
compared with PCT <0.08 ng/mL group (5-year survival 
rate with PCT ≥0.08 ng/mL; 59.1% vs. with PCT <0.08 ng/
mL; 92.7%, log-rank test p = 0.0031).
Furthermore, we evaluated the risk factors for cancer-
specific RFS in these patients. The univariate analysis re-
vealed that tumor diameter, TNM classification, CEA, 
and POI were identified as significant risk factors for can-
cer-specific RFS. Finally, TNM classification was detected 
as an independent risk factor for cancer-specific RFS in 
these patients (Table 3).
Discussion
The measurement of PCT is commonly used in the 
world to assist in the diagnosis of bacterial infection. In 
the 2016 Surviving Sepsis Campaign guideline, it is sug-
gested that measurement of PCT levels can also be used 
to support shortening the duration of antimicrobial ther-
apy in septic patients [13]. We also found the significant 
elevation in PCT levels at POD1 in patients with POI; 
however, the diagnostic impact of PCT at POD1 for POI 
was lower than that of CRP at POD1, 3, and 7 in this study 
(data not shown) as previously discussed [14].
The significant relationship between preoperative 
PCT and malignant tumors was recently reported [10]. 
The elevated PCT levels are related to disease stage in sol-
id cancer patients [15]. Other studies also reported that 
PCT level was an important prognostic factor for patients 
with hepatocellular carcinoma [16], neuroendocrine neo-
plasms of digestive system [17], and lung cancer [18]. 
Collectively, our finding seems to be consistent with re-
cent findings related to PCT and malignant tumors.
Previous studies have reported the usefulness of the GPS 
for the prediction of postoperative mortality in CRC pa-
tients [19]. Therefore, we compared PCT with mGPS in 
terms of prognostic significance for cancer-specific OS in 
CRC patients in this study. Finally, we found that PCT but 
not mGPS was one of the significant risk factors for cancer-
specific OS in Stage I–III patients by univariate and multi-
variate analysis, although we found statistically significant 
association with mGPS and cancer-specific OS/RFS in all 
Stage 0–IV patients (data not shown). The exclusion of in-
competent 62 patients due to no PCT measurements, and 
so on before surgery may influence our findings in statisti-
cal analysis of mGPS for cancer-specific OS/RFS.
Preoperative PCT appeared to be associated with poor 
OS but not RFS in Stage I–III patients after surgery. There 
was no significant difference in therapeutic strategies, such 
as surgery and chemotherapy, after relapse of cancer de-
pending on preoperative PCT; however, the period from 
detection of relapse to cancer-specific death was signifi-
cantly shorter in high preoperative PCT patients than that 
in low preoperative PCT (data not shown). This rapid tu-
mor progression after relapse of cancer observed in high 
preoperative PCT patients may be related to the increased 
systemic inflammatory condition in such patients since 
perioperative systemic inflammation and sepsis are recog-
nized as a risk for the progression of CRC [20]. The increas-
ing evidence also indicates that chronic inflammation plays 
a pivotal role in tumor development, as well as progression, 
metastasis, and resistance to chemotherapy [21].
The systemic PCT appeared to be produced in the liver 
and peripheral mononuclear cells under the influence of 
cytokines and endotoxin [22]. The recent study demon-
strated that the traditional beneficial bacteria such as Lac-
tobacillus and Bifidobacterium decreased significantly and 
the carcinogenic bacteria such as Enterobacteriaceae and 
Fusobacterium nucleatum were significantly increased, 
which was associated with gut mucosal barrier dysfunction 
in early-stage CRC patients with the increased levels of plas-
ma endotoxin [23]. Furthermore, the detection of micro-
bial DNA fragments in the blood of CRC patients was cor-
related with shorter survival [24]. These leakage of endo-
toxin and microbial fragments into the circulation 
accompanied with dysbiosis of the gut microbiome in CRC 
patients may be related to preoperative elevation of PCT 
observed in our study. The disease progression and prog-
nosis in cancer patients are not only determined by the local 
characteristics of the tumor but also by the systemic host 
immune and inflammatory response; therefore, we believe 
that preoperative evaluation of inflammatory status mea-
sured by PCT especially detecting bacterial infection might 
have clinical impact compared to CRP, mGPS, and PNI for 
patients with CRC receiving surgery.
There are some limitations to this study. The first lim-
itation is its retrospective and single-institutional charac-
teristics and small sample size. Second, the mechanism of 
PCT elevation before surgery was not clarified in this 
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study. To further understand the clinical relevance of pre-
operative PCT in CRC patients, a prospective study with 
large sample numbers is needed.
Conclusion
Our findings suggested that high preoperative PCT 
values in CRC patients appeared to be associated with 
poor OS but not RFS following surgical treatments.
Statement of Ethics
Informed consent was obtained from each patient prior to sur-
gery. This study was performed in accordance with the Declaration 
of Helsinki and was approved by the human ethics review commit-
tee in Shiga University of Medical Science (Approved ID:29-028).
The authors declare that they have no competing interests.
Conflict of Interest Statement
All authors declare that they have no possible conflicts of inter-
est.
Funding Sources
This study was supported by a JSPS KAKENHI grant (No. 
20K09005; Japan Grant-in-Aid for Scientific Research (C)).
Author Contributions
T.M., T.S., T.U., M.K., H.O., T.Y., H.I., S.K., E.M., Y.E., and 
M.T. analyzed and interpreted the patient data regarding the 
colorectal cancer. T.M. and T.S. were major contributors in writ-
ing the manuscript. All authors read and approved the final manu-
script.
References
 1 Brenner H, Kloor M, Pox CP. Colorectal can-
cer. Lancet. 2014; 383(9927): 1490–502.
 2 Terzic J, Grivennikov S, Karin E, Karin M. In-
flammation and colon cancer. Gastroenterol-
ogy. 2010; 138: 2101–14 e2105.
 3 McMillan DC, Canna K, McArdle CS. Sys-
temic inflammatory response predicts surviv-
al following curative resection of colorectal 
cancer. Br J Surg. 2003; 90(2): 215–9.
 4 Tanaka H, Muguruma K, Toyokawa T, Kubo 
N, Ohira M, Hirakawa K. Differential impact 
of the neutrophil-lymphocyte ratio on the 
survival of patients with stage IV gastric can-
cer. Dig Surg. 2014; 31(4–5): 327–33.
 5 Kanda M, Fujii T, Kodera Y, Nagai S, Takeda 
S, Nakao A. Nutritional predictors of postop-
erative outcome in pancreatic cancer. Br J 
Surg. 2011; 98(2): 268–74.
 6 Proctor MJ, Morrison DS, Talwar D, Balmer 
SM, Fletcher CD, O'Reilly DS, et al. A com-
parison of inflammation-based prognostic 
scores in patients with cancer. A glasgow in-
flammation outcome study. Eur J Cancer. 
2011; 47(17): 2633–41.
 7 Assicot M, Gendrel D, Carsin H, Raymond J, 
Guilbaud J, Bohuon C. High serum procalci-
tonin concentrations in patients with sepsis 
and infection. Lancet. 1993; 341(8844): 515–8.
 8 Iida H, Maehira H, Mori H, Tani M. Serum 
procalcitonin as a predictor of infectious 
complications after pancreaticoduodenecto-
my: review of the literature and our experi-
ence. Surg Today. 2020 Feb; 50(2): 87–96.
 9 Shimizu T, Obata T, Sonoda H, Akabori H, Mi-
yake T, Yamamoto H, et al. Diagnostic poten-
tial of endotoxin scattering photometry for sep-
sis and septic shock. Shock. 2013; 40(6): 504–11.
10 Cotoi OS, Manjer J, Hedblad B, Engström G, 
Melander O, Schiopu A. Plasma procalcito-
nin is associated with all-cause and cancer 
mortality in apparently healthy men: a pro-
spective population-based study. BMC Med. 
2013; 11: 180.
11 Shimizu T, Hanasawa K, Sato K, Umeki M, 
Koga N, Naganuma T, et al. Perforation 
PMXTSGiSPwC: the clinical significance of 
serum procalcitonin levels following direct 
hemoperfusion with polymyxin B-immobi-
lized fiber column in septic patients with 
colorectal perforation. Eur Surg Res. 2009; 42: 
109–17.
12 Horan TC, Andrus M, Dudeck MA. CDC/
NHSN surveillance definition of health care-
associated infection and criteria for specific 
types of infections in the acute care setting. 
Am J Infect Control. 2008; 36(5): 309–32.
13 Rhodes A, Evans LE, Alhazzani W, Levy MM, 
Antonelli M, Ferrer R, et al. Surviving sepsis 
campaign: international guidelines for man-
agement of sepsis and septic shock: 2016. In-
tensive Care Med. 2017; 43(3): 304–77.
14 Reith HB, Mittelkötter U, Debus ES, Küssner 
C, Thiede A. Procalcitonin in early detection 
of postoperative complications. Dig Surg. 
1998; 15(3): 260–5.
15 Matzaraki V, Alexandraki KI, Venetsanou K, 
Piperi C, Myrianthefs P, Malamos N, et al. 
Evaluation of serum procalcitonin and inter-
leukin-6 levels as markers of liver metastasis. 
Clin Biochem. 2007; 40(5–6): 336–42.
16 Shen H, Zheng S, Chen R, Jin X, Xu X, Jing C, 
et al. Prognostic significance of serum procalci-
tonin in patients with unresectable hepatocel-
lular carcinoma treated with transcatheter arte-
rial chemoembolization: a retrospective analy-
sis of 509 cases. Medicine. 2017; 96(28): e7438.
17 Chen L, Zhang Y, Lin Y, Deng L, Feng S, Chen 
M, et al. The role of elevated serum procalci-
tonin in neuroendocrine neoplasms of diges-
tive system. Clin Biochem. 2017; 50: 982–7.
18 Patout M, Salaün M, Brunel V, Bota S, Cauliez 
B, Thiberville L. Diagnostic and prognostic 
value of serum procalcitonin concentrations 
in primary lung cancers. Clin Biochem. 2014; 
47(18): 263–7.
19 Sugimoto K, Komiyama H, Kojima Y, Goto 
M, Tomiki Y, Sakamoto K. Glasgow prognos-
tic score as a prognostic factor in patients un-
dergoing curative surgery for colorectal can-
cer. Dig Surg. 2012; 29(6): 503–9.
20 Carroll GM, Burns GL, Petit JA, Walker MM, 
Mathe A, Smith SR, et al. Does postoperative 
inflammation or sepsis generate neutrophil 
extracellular traps that influence colorectal 
cancer progression? A systematic review. 
Surg Open Sci. 2020; 2(2): 57–69.
21 Liu J, Lin PC, Zhou BP. Inflammation fuels 
tumor progress and metastasis. Curr Pharm 
Des. 2015; 21(21): 3032–40.
22 Oberhoffer M, Stonans I, Russwurm S, 
Stonane E, Vogelsang H, Junker U, et al. Pro-
calcitonin expression in human peripheral 
blood mononuclear cells and its modulation 
by lipopolysaccharides and sepsis-related cy-
tokines in vitro. J Lab Clin Med. 1999; 134(1): 
49–55.
23 Liu X, Cheng Y, Shao L, Ling Z. Alterations of 
the predominant fecal microbiota and disrup-
tion of the gut mucosal barrier in patients 
with early-stage colorectal cancer. Biomed 
Res Int. 2020; 2020: 2948282.
24 Messaritakis I, Vogiatzoglou K, Tsantaki K, 
Ntretaki A, Sfakianaki M, Koulouridi A, et 
al. The prognostic value of the detection of 
microbial translocation in the blood of 
colorectal cancer patients. Cancers. 2020; 
12(4): 1058.
